Testing a new injection to lower blood pressure in kidney disease patients

Plain-English translation of NCT07483372 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage study testing whether , a new medication injected near the kidneys, can safely lower blood pressure in people whose high blood pressure hasn't responded well to standard medications. Researchers believe this treatment works by affecting nerves near the kidneys that help control blood pressure. The study will enroll just 3 people to first see if the injection is safe.

Many people with kidney disease have high blood pressure that doesn't respond to the usual medications, which puts them at risk for serious heart and kidney complications. This trial explores whether delivering treatment directly near the kidneys might offer a new option for these patients.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with resistant hypertension (high blood pressure that hasn't improved despite taking at least 3 different blood pressure medications, including a water pill, for at least 4 weeks)
you have moderate to severe chronic kidney disease with an eGFR between 15 and 40
your blood pressure readings remain high at the start of the study despite your current medications
you have been taking stable doses of your blood pressure medications for at least 4 weeks and can keep them stable during the study
you are willing to use effective birth control for at least 1 year after the injection (if applicable)

You likely don't qualify if…

you have secondary high blood pressure caused by a specific kidney or adrenal gland condition (like renal artery stenosis or pheochromocytoma)
you have a single kidney, polycystic kidney disease, or other structural kidney abnormalities
you have serious heart conditions such as severe heart failure, recent heart attack or stroke, or serious heart rhythm problems that are not controlled
you have abnormal liver function or significant blood clotting disorders
you have Type 1 diabetes or severe anemia

What participation looks like

If you qualify, you will receive one injection of the medication into the fatty tissue around both kidneys during a single procedure. After that, researchers will monitor your blood pressure and kidney function over time through office visits and ambulatory monitoring to see if the treatment works and remains safe. The study will track your response to help determine if this new approach is worth testing further in larger trials.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

China

Suzhou Municipal Hospital, Suzhou, Jiangsu